Rutgers Cancer Institute of New Jersey

What Rutgers Cancer Institute of New Jersey does

Rutgers Cancer Institute of New Jersey is the only National Cancer Institute-designated Comprehensive Cancer Center in New Jersey, established in 1991 and operating as part of Rutgers Biomedical and Health Sciences within Rutgers, The State University of New Jersey. The institution provides comprehensive cancer care across adult and pediatric oncology, with service lines spanning surgical oncology (including robotic-assisted and HIPEC), medical oncology, radiation oncology (proton therapy, Gamma Knife, SBRT, brachytherapy, Lutathera infusion), hematopoietic stem cell transplantation and CAR T-cell therapy, precision medicine with genomic analysis, and a clinical trials program including Phase I investigational therapeutics. It operates through a strategic partnership with RWJBarnabas Health, the state's largest academic healthcare system, with cancer care delivered across the Jack & Sheryl Morris Cancer Center (a freestanding cancer hospital in New Brunswick and one of only 13 in the United States), the Melchiorre Cancer Center (a 137,000-square-foot outpatient facility in Livingston that opened June 2026), and a planned southern hub at Vogel Medical Campus in Tinton Falls scheduled for 2027.

The business model is non-profit academic medicine, generating revenue through patient care services billed primarily through the RWJBarnabas Health network, supplemented by NCI research funding, philanthropic grants (e.g., $600,000 from V Foundation in 2019), and the $1.5 billion statewide capital investment from RWJBarnabas Health underwriting facility expansion. The Morris Cancer Center treated 85,000+ patients in its first year, delivering over 23,000 chemotherapy infusions, nearly 20,000 radiation treatments, and 1,900+ surgical procedures, indicating substantial operational scale. Technology infrastructure includes proprietary computational tools (PRISM for tumor microbial signal analysis with above-90% sensitivity/specificity and filed IP for commercial applications), digital twin simulation for clinic workflow optimization, and research programs organized into five core areas covering cancer metabolism, genomic instability, pharmacology, clinical investigations, and prevention. Customer acquisition relies on physician referrals and direct patient contact via the 844-CANCERNJ line and MyChart portal, with no publicly disclosed pricing.

Name

Rutgers Cancer Institute of New Jersey

Legal name

Rutgers Cancer Institute of New Jersey

Website

https://cinj.org

Company type

Private

Founded year

1991

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Rutgers Cancer Institute of New Jersey is the state's only NCI-designated Comprehensive Cancer Center, providing comprehensive cancer care, clinical trials, and research across adult and pediatric oncology through a strategic partnership with RWJBarnabas Health spanning New Jersey.

Ownership category

akta.pro rank

Product category

Oncology Services

NAICS

Specialty (except Psychiatric and Substance Abuse) Hospitals (622310), Offices of Physicians (62111), Ambulatory Health Care Services (621)

SIC

Services-Hospitals (8060), Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Specialty Outpatient Facilities, Nec (8093)

akta.pro primary industry

Oncology & Cancer Specialty Hospitals (HLAFAHAC)

Keywords

• Oncology treatment services
• Cancer clinical trials
• Radiation oncology therapy
• Surgical oncology services
• Cancer research programs

Headquarters

HQ city

New Brunswick

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

1. Patient Care Services: Rutgers Cancer Institute generates revenue through providing comprehensive cancer care services including chemotherapy infusions, radiation treatments, surgical procedures, and clinical trials access. Services are provided through partnership with RWJBarnabas Health network of hospitals.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels6 records

Core offering

Rutgers Cancer Institute of New Jersey is the state's first and only National Cancer Institute-designated Comprehensive Cancer Center, providing comprehensive cancer care including surgical oncology, medical oncology, radiation oncology, precision medicine, pediatric oncology, genetic counseling, and access to clinical trials. Services are delivered through the Jack & Sheryl Morris Cancer Center (a freestanding cancer hospital), the Melchiorre Cancer Center, and a statewide partnership network with RWJBarnabas Health, supported by five core research programs and multiple centers of excellence.

Product overview

Rutgers Cancer Institute of New Jersey is New Jersey's only NCI-designated Comprehensive Cancer Center, operating in partnership with RWJBarnabas Health. The institution offers a comprehensive cancer care ecosystem comprising the Jack & Sheryl Morris Cancer Center (the state's only freestanding cancer hospital), the Melchiorre Cancer Center (outpatient facility), and multiple specialty oncology programs covering adult and pediatric cancers. Services span surgical oncology, medical oncology, radiation oncology, precision medicine, clinical trials, genetic counseling, and patient support services. The institute's research infrastructure includes five core research programs and several centers of excellence focused on cancer metabolism, immunology, and health equity.

Differentiator

Problem solved

Functional benefit

Brands

• Jack & Sheryl Morris Cancer Center: New Jersey's only freestanding cancer hospital located in New Brunswick
• Melchiorre Cancer Center
• RWJBarnabas Health Cancer Care Network

Products and services

• Adult Oncology Programs Comprehensive cancer treatment programs across multiple adult cancer types, providing specialized multidisciplinary care for cancer patients in New Jersey.
• Radiation Oncology Services Advanced radiation therapy treatments for cancer patients, including proton therapy, Gamma Knife, stereotactic body radiotherapy, brachytherapy, and Lutathera infusion treatment.
• Clinical Trials Program Access to innovative clinical trials across multiple cancer types for cancer patients, including immunotherapy trials, precision medicine trials, and Phase I investigational therapeutics.
• Surgical Oncology Fellowship-trained surgical oncology service offering minimally invasive techniques including laparoscopic and robotic-assisted surgery, with expertise in HIPEC treatment for peritoneal metastases.
• Precision Medicine Oncology Genomic analysis and targeted therapies tailored to individual patient tumors, including molecular tumor board and precision medicine clinical trials for cancer patients.
• Pediatric Hematology/Oncology Program Specialized cancer care for pediatric patients including stem cell transplantation and cellular therapies, with dedicated pediatric programs and family support services.
• Patient Support Services Comprehensive support services for cancer patients including social work services, integrative oncology (movement, touch, diet & nutrition, mindfulness), palliative medicine, and survivorship programs.
• Genetic Counseling and Risk Assessment (LIFE Center) Genetic counseling and testing services for cancer risk assessment, helping patients understand hereditary cancer risks and make informed decisions.

Quantifiable outcome

• 85,000+ patients treated in first year of Jack & Sheryl Morris Cancer Center operation with over 23,000 chemotherapy infusions, nearly 20,000 radiation treatments, and 1,900+ surgical procedures
• +2 more outcomes

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Four partnerships are on record, tiered core and flagship.

• Cooperman Barnabas Medical CentercoreStrategic or Co-development Partner · 22 June 2026Location of the Melchiorre Cancer Center, a five-story, 137,000-square-foot outpatient oncology facility representing a $225 million investment. Part of RWJBarnabas Health network and home to the Chief of Surgical Oncology & Hepatopancreatobiliary Surgery.
• RWJBarnabas HealthflagshipStrategic or Co-development PartnerStrategic partnership between Rutgers Cancer Institute (New Jersey's only NCI-designated Comprehensive Cancer Center) and RWJBarnabas Health (the state's largest academic health care system) to provide comprehensive cancer care statewide. This partnership encompasses the Jack & Sheryl Morris Cancer Center (freestanding cancer hospital), the Melchiorre Cancer Center in Livingston, and planned facilities at Vogel Medical Campus in Tinton Falls. The collaboration aligns Rutgers' education, research, and clinical activities with RWJBarnabas Health's statewide hospital network covering eight counties with five million people.
• Princeton UniversitycoreStrategic or Co-development PartnerResearch consortium partnership with Princeton University as part of Rutgers Cancer Institute's NCI-designated Comprehensive Cancer Center structure. Collaborates on scientific discovery into cancer treatment, prevention, and diagnosis. Includes joint summer internship program for students.
• Rutgers Robert Wood Johnson Medical SchoolcoreStrategic or Co-development PartnerAcademic partnership with Rutgers Robert Wood Johnson Medical School for medical education, research, and clinical training. Robert Wood Johnson University Hospital serves as the principal teaching hospital for the medical school.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Memorial Sloan Kettering Cancer Center: Memorial Sloan Kettering is an NCI-designated Comprehensive Cancer Center located in New York City, providing multidisciplinary cancer care, research, and clinical trials across all major oncology specialties. It is the most direct peer given overlapping NCI Comprehensive status, comparable clinical trial portfolio, and overlapping NJ-NY patient catchment.
• Penn Medicine Abramson Cancer Center: University of Pennsylvania's NCI-designated Comprehensive Cancer Center offers multidisciplinary cancer treatment, clinical trials, proton therapy, and CAR T-cell therapy in Philadelphia. A direct peer given NCI Comprehensive status, comparable clinical research intensity, and geographic overlap into southern NJ markets.
• Fox Chase Cancer Center: Fox Chase Cancer Center in Philadelphia is an NCI-designated Comprehensive Cancer Center with a long history of clinical and translational cancer research. Direct peer competing for southern NJ patients given geographic proximity and overlapping specialty oncology programs.
• Yale Cancer Center: Yale Cancer Center is an NCI-designated Comprehensive Cancer Center in New Haven, CT offering multidisciplinary oncology care, clinical trials, and translational research. Comparable peer in scope, NCI designation, and academic medical center structure; competes indirectly for regional patients.
• Columbia Herbert Irving Comprehensive Cancer Center: Columbia University's NCI-designated Comprehensive Cancer Center in New York City provides multidisciplinary oncology care, research, and clinical trials. Direct peer given NCI Comprehensive designation, academic structure, and overlapping NY-NJ patient population.

Broad incumbents

• Johns Hopkins Sidney Kimmel Comprehensive Cancer Center: Johns Hopkins' NCI-designated Comprehensive Cancer Center is one of the most prominent academic cancer centers in the US, with deep research portfolio, proton therapy, and CAR T-cell capabilities. Broader incumbent peer in scale and research intensity, providing a benchmark for top-tier academic oncology.
• Dana-Farber Cancer Institute: Dana-Farber Cancer Institute in Boston is an NCI-designated Comprehensive Cancer Center affiliated with Harvard Medical School, recognized for clinical excellence and research. Broader incumbent peer in scope, NCI designation, and academic affiliation model.
• MD Anderson Cancer Center: The University of Texas MD Anderson Cancer Center is the largest NCI-designated Comprehensive Cancer Center in the US, treating more cancer patients than any other center. Broad incumbent peer that sets the benchmark for academic oncology scale, clinical trial volume, and translational research output.
• Massachusetts General Hospital Cancer Center: Mass General Cancer Center in Boston is an NCI-designated Comprehensive Cancer Center embedded within a major academic medical center. Comparable in academic structure, multidisciplinary care model, and clinical trial breadth; broader incumbent given larger hospital system footprint.

Emerging players

• City of Hope Comprehensive Cancer Center: City of Hope is an NCI-designated Comprehensive Cancer Center based in California that has expanded aggressively across the US, including planned NJ/NY presence. Comparable in NCI Comprehensive designation and academic cancer care delivery, and a relevant emerging competitor for NJ patient capture given its national expansion strategy.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key highlights7 records

Customer concentration

• Xx.com/RutgersCancer
• YouTubeyoutube.com/user/CancerInstNJ
• Facebookfacebook.com/TheCINJ
• LinkedInlinkedin.com/company/the-cancer-institute-of-new-jersey
• Instagraminstagram.com/rutgerscancerinstitute

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Rutgers Cancer Institute of New Jersey